<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729257</url>
  </required_header>
  <id_info>
    <org_study_id>ICBE-S-000233</org_study_id>
    <nct_id>NCT04729257</nct_id>
  </id_info>
  <brief_title>Norms Expansion and Validation for IntelliSpace Cognition</brief_title>
  <official_title>Norms Expansion and Validation for IntelliSpace Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Electronics Nederland B.V. acting through Philips CTO organization</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research America Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qserve</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philips Electronics Nederland B.V. acting through Philips CTO organization</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include&#xD;
      ages 18-49 and 80+ and aims to validate two new digital tests.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Actual">July 2, 2021</completion_date>
  <primary_completion_date type="Actual">July 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Scores digital (ISC) tests [Time Frame: 1.5 hours]. Scores retrieved from all cognitive tests on the ISC platform.</measure>
    <time_frame>1.5 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>or 1.5 hours]. Scores retrieved from Symbol Digit Modalities Test (SDMT) + Naming Test (NT) or all paper-based cognitive tests</measure>
    <time_frame>0.75 h or 1.5 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Cognitive Functioning of Healthy Individuals</condition>
  <arm_group>
    <arm_group_label>Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Validation, 18+)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (Validation, 18+)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E (Norms, 18-49 years)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F (Norms, 80-95 years)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Philips IntelliSpace Cognition (ISC).</intervention_name>
    <description>Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.</description>
    <arm_group_label>Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)</arm_group_label>
    <arm_group_label>Group B (Validation, 18+)</arm_group_label>
    <arm_group_label>Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)</arm_group_label>
    <arm_group_label>Group E (Norms, 18-49 years)</arm_group_label>
    <arm_group_label>Group F (Norms, 80-95 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Paper-Pencil Tests.</intervention_name>
    <description>The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.</description>
    <arm_group_label>Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)</arm_group_label>
    <arm_group_label>Group B (Validation, 18+)</arm_group_label>
    <arm_group_label>Group D (Validation, 18+)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is 18 years or older.&#xD;
&#xD;
          -  Participant's primary language (language most often spoken) must be American English.&#xD;
&#xD;
          -  Participant is able to see well (naturally or corrected by means of eyeglasses or&#xD;
             lenses).&#xD;
&#xD;
          -  Participant is able to hear well (naturally of corrected by means of a hearing aid).&#xD;
&#xD;
          -  Participant is able to use their fingers, hands and arms to write symbols.&#xD;
&#xD;
          -  Participant has valid health insurance in USA.&#xD;
&#xD;
          -  Participant is able to give informed consent.&#xD;
&#xD;
          -  Participant is able to understand test instructions and participate fully in testing.&#xD;
&#xD;
          -  Participant has normal fine and gross motor ability.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is 18 years or older.&#xD;
&#xD;
          -  Participant's primary language (language most often spoken) must be American English.&#xD;
&#xD;
          -  Participant is able to see well (naturally or corrected by means of eyeglasses or&#xD;
             lenses).&#xD;
&#xD;
          -  Participant is able to hear well (naturally of corrected by means of a hearing aid).&#xD;
&#xD;
          -  Participant is able to use their fingers, hands and arms to write symbols.&#xD;
&#xD;
          -  Participant has valid health insurance in USA.&#xD;
&#xD;
          -  Participant is able to give informed consent.&#xD;
&#xD;
          -  Participant is able to understand test instructions and participate fully in testing.&#xD;
&#xD;
          -  Participant has normal fine and gross motor ability.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is currently admitted to a hospital, assisted living, nursing home or a&#xD;
             psychiatric facility.&#xD;
&#xD;
          -  Participant is diagnosed with a neurological disorder or disease that may affect&#xD;
             cognitive functioning (e.g., Parkinson's, brain tumor, stroke, Traumatic Brain Injury&#xD;
             (TBI), epilepsy [if # seizures â‰¤ 2 and not receiving ongoing treatment for seizures,&#xD;
             and not currently seeking medical evaluation or attention related to seizures,&#xD;
             participant can be accepted], encephalitis, dementia).&#xD;
&#xD;
          -  Participant is diagnosed with a language disorder or aphasia (expressive or mixed&#xD;
             receptive/expressive) [if articulation disorder, participant can be accepted].&#xD;
&#xD;
          -  Participant is diagnosed with a learning disorder.&#xD;
&#xD;
          -  Participant is diagnosed with an autoimmune disorder that may affect cognitive&#xD;
             functioning (e.g., LUPUS, Multiple Sclerosis).&#xD;
&#xD;
          -  Participant is or was diagnosed with a current or past psychotic disorder (e.g.,&#xD;
             schizophrenia).&#xD;
&#xD;
          -  Participant is diagnosed with a severe mood disorder [if Major Depressive Disorder in&#xD;
             remission or with no current episode or Dysthymic Disorder or Adjustment Disorder,&#xD;
             participant can be accepted].&#xD;
&#xD;
          -  Participant is diagnosed with a severe anxiety disorder [if Phobia or Anxiety&#xD;
             disorders with symptoms not significant enough to interfere with test performance,&#xD;
             participant can be accepted].&#xD;
&#xD;
          -  Participant is or was diagnosed with current or past Autism Spectrum Disorder or&#xD;
             Intellectual Disability.&#xD;
&#xD;
          -  Participant is diagnosed with a current substance abuse or dependence [if in remission&#xD;
             â‰¥ 1 year, participant can be accepted].&#xD;
&#xD;
          -  Participant has carried a substance abuse or dependence diagnosis for more than 10&#xD;
             years at any point in their life.&#xD;
&#xD;
          -  Participant has an average alcohol consumption of 4 or more units per day.&#xD;
&#xD;
          -  Participant uses medical marijuana.&#xD;
&#xD;
          -  Participant uses recreational marijuana more than once a week.&#xD;
&#xD;
          -  Participant uses recreational drugs other than alcohol and marijuana in the last 6&#xD;
             months (e.g., cocaine, ecstasy, LSD).&#xD;
&#xD;
          -  Participant has been unconscious related to traumatic brain injury or 'medical&#xD;
             condition' for more than 20 minutes [if medication-induced or due to heat stroke,&#xD;
             participant can be accepted].&#xD;
&#xD;
          -  Participant has stayed in a hospital overnight due to a head injury.&#xD;
&#xD;
          -  Participant has had a medical event requiring resuscitation in which they were&#xD;
             non-responsive for more than 15 minutes.&#xD;
&#xD;
          -  Participant has received chemotherapy treatment in the past 2 months.&#xD;
&#xD;
          -  Participant has received electroconvulsive therapy (ECT).&#xD;
&#xD;
          -  Participant has received radiation to the central nervous system.&#xD;
&#xD;
          -  Participant experiences a physical condition or illness that interferes with normal&#xD;
             cognitive functioning at work, school, Instrumental Activities of Daily Living (IADLs)&#xD;
             etc. [if diabetes or hypothyroidism or hypertension and if controlled, participant can&#xD;
             be accepted].&#xD;
&#xD;
          -  Participant is currently taking anti-convulsants (Depakote, Lamictal or Lyrica,&#xD;
             Gabapentin, Keppra, Topamax, Divalproex Sodium, Valproate Sodium, Levetiracetam,&#xD;
             Lamotrigine, Pregabalin, Topiramate).&#xD;
&#xD;
          -  Participant is currently taking anti-psychotics (Abilify, Rexulti, Zyprexa, Clozaril,&#xD;
             Clozapine, Latuda, Seroquel, Risperdal, Risperidone, Aripipazle, Bexipiprazole,&#xD;
             Olanzapine, Lurasidone HCL, Quetiapine).&#xD;
&#xD;
          -  Participant is currently taking benzodiazepines (Diazepams, Valium, Klonopin, Ativan,&#xD;
             Xanax, Lorazepam, Alprazolam, Clonazepam).&#xD;
&#xD;
          -  Participant is currently taking psychostimulants (Amphetamines, Adderall, Ritalin,&#xD;
             Methamphetamines, Dextroamphetamine, Methylphenidate HCL). [if coffee, participant can&#xD;
             be accepted].&#xD;
&#xD;
          -  Participant is currently taking opioids (Oxycontin, Tramadol, Codeine, Dilaudid,&#xD;
             Suboxone, Oxycodone, Percocet, Buprenorhine, Naloxone).&#xD;
&#xD;
          -  Participant is currently taking antidepressants (Amitriptyline, Elavil, Pamelor,&#xD;
             Tofranil, Vivactil, Imipramine, Protriptyline HCL). [if antidepressant that are not&#xD;
             tricyclic, participant can be accepted].&#xD;
&#xD;
          -  Participant is currently taking oxybutynin (Ditropan).&#xD;
&#xD;
          -  Participant is currently seeking medical diagnostic procedures for cognitive&#xD;
             difficulties from a medical professional.&#xD;
&#xD;
          -  Participant has received neuropsychological testing before. [if previous MMSE(-2) or&#xD;
             MoCA testing more than 6 months prior, participant can be accepted].&#xD;
&#xD;
          -  Participant shows evidence of current cognitive impairment.&#xD;
&#xD;
          -  Participant displays disruptive behavior or insufficient compliance with testing to&#xD;
             ensure a valid assessment.&#xD;
&#xD;
          -  Participant is primarily nonverbal or uncommunicative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research America Inc.</name>
      <address>
        <city>Newtown Square</city>
        <state>Pennsylvania</state>
        <zip>19073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive model</keyword>
  <keyword>Cognitive assessment</keyword>
  <keyword>Digital cognitive tests</keyword>
  <keyword>Automated scoring</keyword>
  <keyword>Algorithms</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

